Fear Factor

Oct 26, 2023

This Halloween amid all the ghosts, goblins, ghouls, spiders, snakes, skulls, and skeletons that you may encounter remember FDR’s admonition that “the only thing we have to fear is fear itself.”

To that iconic, hope-bringing phrase, we would add, “and a lack of effective therapeutics.” Such is the case for several conditions including cancer, severe oral mucositis, neurodegenerative diseases, and endometriosis where current therapies are inadequate or less than optimal.

Into this breach potentially comes EpicentRx’s lead therapeutics, AdAPT-001 and RRx-001/nibrozetone. The former is an oncolytic adenovirus that carries a TGF-β trap for the treatment of liver-predominant colorectal cancer and sarcoma and the latter is a multitargeted small molecule NLRP3 inhibitor for the treatment of small cell lung cancer (SCLC), severe oral mucositis, neurodegenerative diseases, and endometriosis.

It is our sincerest hope that AdAPT-001 and RRx-001/nibrozetone will both demonstrate the talismanic potential to ward off/scare away these dreaded, fearful conditions not just on Halloween but on all days of the year.